Majid Mirsadraee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Majid Mirsadraee has a total of 112 co-authors. Here are the top co-authors by number of shared publications:
Shadi Ghaffari
Department of Biology, Damghan Branch, Islamic Azad University, Damghan, Iran
7 shared publicationsDavood Attaran
Pulmonologist, Lung Disease Research Center, Faculty of Medicine Mashhad University of Medicine Sciences, Mashhad, Iran
5 shared publications- Amirhossein Hashemi Attar
Department of Radiology, Mashhad Medical Sciences Branch, Islamic Azad University, Mashhad, Iran
3 shared publications - Mojtaba Meshkat
Department of Biostatistics, School of Paramedicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 shared publications Parisa Saeedi
Department of Urology, Akbar Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
3 shared publications- Roshanak Salari
Department of pharmaceutical sciences in Persian Medicine, School of Persian and Complementary Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
3 shared publications
Latest Publications
- Open Access
- 2 July 2026
- Published by Springer Nature in The Egyptian Journal of Bronchology
- Vol. 20 (1)
The role of antileukotriene therapy in COPD management: a systematic review and meta-analysis of randomized controlled trials
Background: Chronic Obstructive Pulmonary Disease (COPD) is a prevalent lung condition that impairs breathing and daily activities, manifesting symptoms such as a persistent cough, shortness of breath, and chest tightness. Antileukotrienes, including Montelukast, Zafirlukast, and Zileuton, are used to manage inflammation in asthma; however, according to the 2025 GOLD reports, their efficacy in treating COPD remains unclear. This systematic review and meta-analysis aim to evaluate the role of antileukotriene therapy in patients with COPD. Method: This systematic review was reported in accordance with the PRISMA guidelines. In July 2023, a comprehensive search was conducted across Scopus, Web of Science, PubMed, Cochrane Library, and Embase. The review included only randomized controlled trials that compared anti-leukotriene agents with a placebo. A meta-analysis was performed on Forced Expiratory Volume in 1 s(FEV1), Leukotriene B4(LTB4), and Myeloperoxidase(MPO), utilizing standardized mean differences(SMD) with a 95% confidence interval(CI). C-reactive protein(CRP), quality of life and adverse events data were summarized narratively. Results: This meta-analysis encompassed nine randomized controlled trials involving a total of 506 participants. The findings indicated that anti-leukotriene therapy led to a significant overall improvement in FEV1 (SMD = 0.63, 95%CI 0.15 to 1.11, p = 0.01), although high heterogeneity was noted(I 2 = 83%). A subgroup analysis focusing specifically on leukotriene receptor antagonists revealed a more consistent and potent effect on FEV1 (SMD = 1.00, 95%CI 0.75 to 1.25, p < 0.001) with low heterogeneity. Notably, both Montelukast(SMD = 1.15) and Zafirlukast(SMD = 0.75) displayed significant benefits. In contrast, no significant improvements were found in the inflammatory markers LTB4 (SMD=-0.42) or MPO (SMD=-0.14). CRP results were inconclusive, while quality of life scores showed improvement in the montelukast groups. Adverse events were comparable between groups or reduced in the experimental group. Conclusion: Analysis indicates that anti-leukotriene therapy, particularly with Montelukast and Zafirlukast, may lead to a modest improvement in lung function and quality of life. Subgroup analyses suggest a potential benefit specifically for Montelukast, although this requires further confirmation. In contrast, Zileuton, which operates via a different mechanism, did not demonstrate any beneficial effects. Given the limitations in sample size and heterogeneity, these findings should be considered exploratory, and additional research is essential to validate these results in larger studies.
- 2 July 2026
- Published by Springer Nature in The Egyptian Journal of Bronchology
- Vol. 20 (1)
Open AccessThe role of antileukotriene therapy in COPD management: a systematic review and meta-analysis of randomized controlled trials
Background: Chronic Obstructive Pulmonary Disease (COPD) is a prevalent lung condition that impairs breathing and daily activities, manifesting symptoms such as a persistent cough, shortness of breath, and chest tightness. Antileukotrienes, including Montelukast, Zafirlukast, and Zileuton, are used to manage inflammation in asthma; however, according to the 2025 GOLD reports, their efficacy in treating COPD remains unclear. This systematic review and meta-analysis aim to evaluate the role of antileukotriene therapy in patients with COPD. Method: This systematic review was reported in accordance with the PRISMA guidelines. In July 2023, a comprehensive search was conducted across Scopus, Web of Science, PubMed, Cochrane Library, and Embase. The review included only randomized controlled trials that compared anti-leukotriene agents with a placebo. A meta-analysis was performed on Forced Expiratory Volume in 1 s(FEV1), Leukotriene B4(LTB4), and Myeloperoxidase(MPO), utilizing standardized mean differences(SMD) with a 95% confidence interval(CI). C-reactive protein(CRP), quality of life and adverse events data were summarized narratively. Results: This meta-analysis encompassed nine randomized controlled trials involving a total of 506 participants. The findings indicated that anti-leukotriene therapy led to a significant overall improvement in FEV1 (SMD = 0.63, 95%CI 0.15 to 1.11, p = 0.01), although high heterogeneity was noted(I 2 = 83%). A subgroup analysis focusing specifically on leukotriene receptor antagonists revealed a more consistent and potent effect on FEV1 (SMD = 1.00, 95%CI 0.75 to 1.25, p < 0.001) with low heterogeneity. Notably, both Montelukast(SMD = 1.15) and Zafirlukast(SMD = 0.75) displayed significant benefits. In contrast, no significant improvements were found in the inflammatory markers LTB4 (SMD=-0.42) or MPO (SMD=-0.14). CRP results were inconclusive, while quality of life scores showed improvement in the montelukast groups. Adverse events were comparable between groups or reduced in the experimental group. Conclusion: Analysis indicates that anti-leukotriene therapy, particularly with Montelukast and Zafirlukast, may lead to a modest improvement in lung function and quality of life. Subgroup analyses suggest a potential benefit specifically for Montelukast, although this requires further confirmation. In contrast, Zileuton, which operates via a different mechanism, did not demonstrate any beneficial effects. Given the limitations in sample size and heterogeneity, these findings should be considered exploratory, and additional research is essential to validate these results in larger studies.
- 28 February 2025
- Published by Knowledge E DMCC in Iranian Journal of Allergy, Asthma and Immunology
- Vol. 24 (1) , 1-11
Investigating the Relationship between FGF2 Gene Expression and Airway Remodeling in Severe Asthma
Severe asthma causes chronic airway inflammation and structural changes in the bronchial wall. Fibroblast growth factor 2 (FGF2) plays an inflammatory role in specific pathways in airway remodeling in asthma. Assessing the relationship between sputum pattern, bronchial thickness by high-resolution computed tomography (HRCT) scan, and FGF2 expression level can evaluate the role of FGF2 in asthma remodeling. The study aimed to investigate the correlation between airway wall thickness and FGF2 gene expression in 100 participants with severe asthma. The method involved measuring airway wall thickness using HRCT and analyzing FGF2 gene expression through real-time reverse transcriptase polymerase chain reaction. The participants were divided into 2 groups based on bronchodilator responsiveness and classified into different asthma phenotypes based on sputum cell count. The baseline data did not show a significant difference between the groups. The study found significant differences in airway variables between different asthma subgroups. FGF2 expression was associated with various characteristics of asthma, including body mass index, forced expiratory volume in 1 second (FEV1), and airway wall thickness. The receiver operating characteristic curve analysis showed that a fold change higher than 2.42 in FGF2 expression indicated asthma. Based on our research, FGF2 may play a critical role in airway thickness regardless of inflammation. We found increased FGF2 levels with disease severity and wall thickness in atopic severe persistent asthma patients with FEV1 below 60%. Further research is needed to understand FGF2's role across broader FEV1 ranges and other phenotypes.
- 28 February 2025
- Published by Knowledge E DMCC in Iranian Journal of Allergy, Asthma and Immunology
- Vol. 24 (1) , 1-11
Investigating the Relationship between FGF2 Gene Expression and Airway Remodeling in Severe Asthma
Severe asthma causes chronic airway inflammation and structural changes in the bronchial wall. Fibroblast growth factor 2 (FGF2) plays an inflammatory role in specific pathways in airway remodeling in asthma. Assessing the relationship between sputum pattern, bronchial thickness by high-resolution computed tomography (HRCT) scan, and FGF2 expression level can evaluate the role of FGF2 in asthma remodeling. The study aimed to investigate the correlation between airway wall thickness and FGF2 gene expression in 100 participants with severe asthma. The method involved measuring airway wall thickness using HRCT and analyzing FGF2 gene expression through real-time reverse transcriptase polymerase chain reaction. The participants were divided into 2 groups based on bronchodilator responsiveness and classified into different asthma phenotypes based on sputum cell count. The baseline data did not show a significant difference between the groups. The study found significant differences in airway variables between different asthma subgroups. FGF2 expression was associated with various characteristics of asthma, including body mass index, forced expiratory volume in 1 second (FEV1), and airway wall thickness. The receiver operating characteristic curve analysis showed that a fold change higher than 2.42 in FGF2 expression indicated asthma. Based on our research, FGF2 may play a critical role in airway thickness regardless of inflammation. We found increased FGF2 levels with disease severity and wall thickness in atopic severe persistent asthma patients with FEV1 below 60%. Further research is needed to understand FGF2's role across broader FEV1 ranges and other phenotypes.
- 17 February 2024
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 326, 117928
Zataria multiflora affects pulmonary function tests, respiratory symptoms, bronchodilator drugs use and hematological parameters in chronic obstructive pulmonary disease patients: A randomized doubled-blind clinical trial
- 17 February 2024
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 326, 117928
Zataria multiflora affects pulmonary function tests, respiratory symptoms, bronchodilator drugs use and hematological parameters in chronic obstructive pulmonary disease patients: A randomized doubled-blind clinical trial
- Open Access
- 30 June 2023
- Published by Korean Pharmacopuncture Institute in Journal of Pharmacopuncture
- Vol. 26 (2) , 124-138
Efficacy of Herbal Medicines on Lung Function in Asthma: a systematic review and meta-analysis of randomized controlled trials
Alireza Derakhshan, Masoumeh Sadeghi, Amir-Mohammad-Hashem Asnaashari, Mohsen Dehghani, Roshanak Salari, Majid Khadem-Rezaiyan, Majid Mirsadraee, Shahin Saeidinejat, Shima Jalali, Shabnam Jalali. J Pharmacopuncture 2023;26:124-38. https://doi.org/10.3831/KPI.2023.26.2.124
- 30 June 2023
- Published by Korean Pharmacopuncture Institute in Journal of Pharmacopuncture
- Vol. 26 (2) , 124-138
Open AccessEfficacy of Herbal Medicines on Lung Function in Asthma: a systematic review and meta-analysis of randomized controlled trials
Alireza Derakhshan, Masoumeh Sadeghi, Amir-Mohammad-Hashem Asnaashari, Mohsen Dehghani, Roshanak Salari, Majid Khadem-Rezaiyan, Majid Mirsadraee, Shahin Saeidinejat, Shima Jalali, Shabnam Jalali. J Pharmacopuncture 2023;26:124-38. https://doi.org/10.3831/KPI.2023.26.2.124
- 25 February 2023
- Published by Knowledge E DMCC in Iranian Journal of Allergy, Asthma and Immunology
- Vol. 22 (1) , 1-11
Itraconazole Improved Bronchial Wall thickness in Severe Persistent Asthma: A Double-blind Placebo-controlled Randomized Clinical Trial
The purpose of this study was to evaluate the effect of 8 months of treatment with itraconazole on airway wall thickness in patients with severe persistent asthma. It was a double-blind, randomized, placebo-controlled clinical trial (IRCT20091111002695N9). Seventy-five subjects with severe persistent asthma received itraconazole (100 mg), prednisolone (5 mg), or placebo twice a day for eight months in three treatment groups (n=25 in each group). The primary objective was to improve the right upper lobe apical segmental bronchus (RB1) wall thickness percentage measured by high-resolution computed tomography scan of the lungs. Other morphometric measurements of RB1, asthma control test (ACT) score, presence of wheezing, dyspnea severity, rate of asthma exacerbation, fractional exhaled nitric oxide (FeNO), and expiratory volume in 1 second (FEV1) were set as the secondary outcomes. Wall thickness percentage reduced significantly from 46% to 43.7% from pre- to post-treatment in the itraconazole-treated subjects. Similarly, lumen area and radius increased significantly in both the prednisolone and itraconazole groups. Itraconazole led to a significant improvement in wheezing, dyspnea severity, FEV1, ACT score, and FeNO. Although prednisolone was also effective in improving pulmonary function tests and ACT scores, it was associated with significantly more side effects than itraconazole. Long-term treatment with itraconazole resulted in a significant reduction in bronchial wall thickness and improvements in clinical findings and pulmonary function tests. Thus, itraconazole could be a helpful add-on treatment option for severe persistent asthma patients to achieve better disease control.
- 25 February 2023
- Published by Knowledge E DMCC in Iranian Journal of Allergy, Asthma and Immunology
- Vol. 22 (1) , 1-11
Itraconazole Improved Bronchial Wall thickness in Severe Persistent Asthma: A Double-blind Placebo-controlled Randomized Clinical Trial
The purpose of this study was to evaluate the effect of 8 months of treatment with itraconazole on airway wall thickness in patients with severe persistent asthma. It was a double-blind, randomized, placebo-controlled clinical trial (IRCT20091111002695N9). Seventy-five subjects with severe persistent asthma received itraconazole (100 mg), prednisolone (5 mg), or placebo twice a day for eight months in three treatment groups (n=25 in each group). The primary objective was to improve the right upper lobe apical segmental bronchus (RB1) wall thickness percentage measured by high-resolution computed tomography scan of the lungs. Other morphometric measurements of RB1, asthma control test (ACT) score, presence of wheezing, dyspnea severity, rate of asthma exacerbation, fractional exhaled nitric oxide (FeNO), and expiratory volume in 1 second (FEV1) were set as the secondary outcomes. Wall thickness percentage reduced significantly from 46% to 43.7% from pre- to post-treatment in the itraconazole-treated subjects. Similarly, lumen area and radius increased significantly in both the prednisolone and itraconazole groups. Itraconazole led to a significant improvement in wheezing, dyspnea severity, FEV1, ACT score, and FeNO. Although prednisolone was also effective in improving pulmonary function tests and ACT scores, it was associated with significantly more side effects than itraconazole. Long-term treatment with itraconazole resulted in a significant reduction in bronchial wall thickness and improvements in clinical findings and pulmonary function tests. Thus, itraconazole could be a helpful add-on treatment option for severe persistent asthma patients to achieve better disease control.
- Open Access
- 1 January 2023
- Vol. 22 (1) , 129-135
Comparison of Longevity in Patients with Idiopathic Pulmonary Fibrosis Using Pirfenidone Versus Triple Therapy with Prednisolone, Azathioprine, and Acetylcysteine.
The effect of the combination of prednisolone, azathioprine, and acetylcysteine for the treatment of Idiopathic pulmonary fibrosis (IPF) is minimal. We aimed to investigate the effect of these drugs in case of intolerance to new anti-fibrotic drugs. This historical prospective study was performed on 91 patients with idiopathic pulmonary fibrosis who were referred to a pulmonologist in Mashhad during 2016-2020. Patients were divided into two groups, Pirfenidone which was prescribed for 46 subjects, and a combination of prednisolone, azathioprine, and acetylcysteine which was prescribed for 45 subjects. Patients were selected by convenience sampling and a life expectancy comparison between the two groups was performed by Cox regression. There were no statistically significant differences between age, gender, and drug type in the two groups at the beginning of treatment. The death rate per year in the triple-drug treatment group was 44.44% (n = 20) and in the Pirfenidone treatment group was 11.08% (n=2). Of the 65 recovered population, 49% (22 patients) were in the triple-drug treatment group, and 78% (36 patients) were in the Pirfenidone treatment group which indicated that Pirfenidone has a significant impact on reducing death rate compared to triple-drug treatment (pvalue=0.003 <0.05). Pirfenidone decreased the risk of death, compared to triple therapy (0.23 when death was set up as one in the triple-therapy group). Pirfenidone has a favorable effect on increasing life expectancy and triple therapy should be considered as short-term only in subjects intolerant to anti-fibrotic.
- 1 January 2023
- Vol. 22 (1) , 129-135
Open AccessComparison of Longevity in Patients with Idiopathic Pulmonary Fibrosis Using Pirfenidone Versus Triple Therapy with Prednisolone, Azathioprine, and Acetylcysteine.
The effect of the combination of prednisolone, azathioprine, and acetylcysteine for the treatment of Idiopathic pulmonary fibrosis (IPF) is minimal. We aimed to investigate the effect of these drugs in case of intolerance to new anti-fibrotic drugs. This historical prospective study was performed on 91 patients with idiopathic pulmonary fibrosis who were referred to a pulmonologist in Mashhad during 2016-2020. Patients were divided into two groups, Pirfenidone which was prescribed for 46 subjects, and a combination of prednisolone, azathioprine, and acetylcysteine which was prescribed for 45 subjects. Patients were selected by convenience sampling and a life expectancy comparison between the two groups was performed by Cox regression. There were no statistically significant differences between age, gender, and drug type in the two groups at the beginning of treatment. The death rate per year in the triple-drug treatment group was 44.44% (n = 20) and in the Pirfenidone treatment group was 11.08% (n=2). Of the 65 recovered population, 49% (22 patients) were in the triple-drug treatment group, and 78% (36 patients) were in the Pirfenidone treatment group which indicated that Pirfenidone has a significant impact on reducing death rate compared to triple-drug treatment (pvalue=0.003 <0.05). Pirfenidone decreased the risk of death, compared to triple therapy (0.23 when death was set up as one in the triple-therapy group). Pirfenidone has a favorable effect on increasing life expectancy and triple therapy should be considered as short-term only in subjects intolerant to anti-fibrotic.
- Open Access
- 2 November 2022
- Published by Hindawi Limited in Journal of Parasitology Research
- Vol. 2022, 1-6
Effective Treatment of Chronic Cough with Tinidazole as the Newest Antiprotozoa against Lophomonas blattarum
Background. Chronic cough is a common problem in the setting of family physicians. Recently, Lophomonas blattarum was considered a cause of respiratory symptoms in children and adults. Objective. This study is aimed at determining the effect of antiprotozoal treatment of Lophomonas in patients with a chronic cough in Mashhad during 2020-2021. Materials and Methods. This study was a randomized clinical trial. In this study, 60 patients with chronic cough and unremarkable imaging findings, who were unresponsive to three steps of standard treatment, were randomly assigned to the treatment, with 2 weeks of tinidazole and placebo. The tinidazole and placebo were prepared in a completely identical shape, and a random assignment was performed by a third party. The primary outcome was a complete resolution of cough. A follow-up of treatment was performed. Data were analyzed using the SPSS software version 25. Results. The basic demographic results showed no significant differences of sex and age between two groups. The results of this study showed a complete resolution of all respiratory symptoms in 40% (12), a complete improvement of cough in 40% (12), and a complete resolution of dyspnea in 50% (10) of the tinidazole group. The remaining showed significant improvement in the severity of cough and dyspnea. Postnasal drip, sputum, body temperature, and airway hyperresponsiveness were improved significantly. After tinidazole treatment, laboratory assessment of bronchial lavage and sputum revealed that 86 percent of smears were converted to negative. Conclusion. Tinidazole effectively resolved the chronic cough and most of the respiratory symptoms. Lophomonas blattarum is a potential mechanism for chronic cough.
- 2 November 2022
- Published by Hindawi Limited in Journal of Parasitology Research
- Vol. 2022, 1-6
Open AccessEffective Treatment of Chronic Cough with Tinidazole as the Newest Antiprotozoa against Lophomonas blattarum
Background. Chronic cough is a common problem in the setting of family physicians. Recently, Lophomonas blattarum was considered a cause of respiratory symptoms in children and adults. Objective. This study is aimed at determining the effect of antiprotozoal treatment of Lophomonas in patients with a chronic cough in Mashhad during 2020-2021. Materials and Methods. This study was a randomized clinical trial. In this study, 60 patients with chronic cough and unremarkable imaging findings, who were unresponsive to three steps of standard treatment, were randomly assigned to the treatment, with 2 weeks of tinidazole and placebo. The tinidazole and placebo were prepared in a completely identical shape, and a random assignment was performed by a third party. The primary outcome was a complete resolution of cough. A follow-up of treatment was performed. Data were analyzed using the SPSS software version 25. Results. The basic demographic results showed no significant differences of sex and age between two groups. The results of this study showed a complete resolution of all respiratory symptoms in 40% (12), a complete improvement of cough in 40% (12), and a complete resolution of dyspnea in 50% (10) of the tinidazole group. The remaining showed significant improvement in the severity of cough and dyspnea. Postnasal drip, sputum, body temperature, and airway hyperresponsiveness were improved significantly. After tinidazole treatment, laboratory assessment of bronchial lavage and sputum revealed that 86 percent of smears were converted to negative. Conclusion. Tinidazole effectively resolved the chronic cough and most of the respiratory symptoms. Lophomonas blattarum is a potential mechanism for chronic cough.
- Open Access
- 30 September 2022
- Published by Korean Pharmacopuncture Institute in Journal of Pharmacopuncture
- Vol. 25 (3) , 233-241
The Effect of Glasthma Syrup in Asthma: a study protocol for a triple-blind randomized controlled trial
Ali Reza Derakhshan, Shahin Saeidinejat, Majid Khadem-Rezaiyan, Amir-Mohammad-Hashem Asnaashari, Majid Mirsadraee, Roshanak Salari, Farahzad Jabbari-Azad, Shima Jalali, Shabnam Jalali. J Pharmacopuncture 2022;25:233-41. https://doi.org/10.3831/KPI.2022.25.3.233
- 30 September 2022
- Published by Korean Pharmacopuncture Institute in Journal of Pharmacopuncture
- Vol. 25 (3) , 233-241
Open AccessThe Effect of Glasthma Syrup in Asthma: a study protocol for a triple-blind randomized controlled trial
Ali Reza Derakhshan, Shahin Saeidinejat, Majid Khadem-Rezaiyan, Amir-Mohammad-Hashem Asnaashari, Majid Mirsadraee, Roshanak Salari, Farahzad Jabbari-Azad, Shima Jalali, Shabnam Jalali. J Pharmacopuncture 2022;25:233-41. https://doi.org/10.3831/KPI.2022.25.3.233
- 1 August 2021
- Published by Elsevier in Respiratory Medicine
- Vol. 185, 106494
Effect of azithromycin on bronchial wall thickness in severe persistent asthma: A double-blind placebo-controlled randomized clinical trial
- 1 August 2021
- Published by Elsevier in Respiratory Medicine
- Vol. 185, 106494
Effect of azithromycin on bronchial wall thickness in severe persistent asthma: A double-blind placebo-controlled randomized clinical trial